Trials / Completed
CompletedNCT01373931
A Study of LY2216684 in Healthy Females
Effect of LY2216684 on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study involves a single dose of 18 milligrams (mg) LY2216684 taken as 1 or 2 tablets by mouth. The study will evaluate effect of LY2216684 on the pharmacokinetics of an oral contraceptive Ortho Cyclen®. This study will run approximately 93 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2216684 | Administered orally |
| DRUG | Ortho Cyclen | 35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2011-06-15
- Last updated
- 2018-10-23
- Results posted
- 2018-10-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01373931. Inclusion in this directory is not an endorsement.